IRWD Aug 2024 10.000 call
| Previous close | 0.4000 |
| Open | 0.4500 |
| Bid | 0.2000 |
| Ask | 0.6000 |
| Strike | 10.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.4500 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 160 |
Business WireIronwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
BOSTON, May 01, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting. DDW is held from May 18-21, 2024, in Washington, D.C.
Business WireIronwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
BOSTON, April 25, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 3416473. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodp
ZacksOPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
